Guselkumab - In Psoriasis and Beyond
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where gus...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Mattioli1885
2024-07-01
|
| Rangatū: | Dermatology Practical & Conceptual |
| Ngā marau: | |
| Urunga tuihono: | https://dpcj.org/index.php/dpc/article/view/4176 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
